Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca study shows limitations of current gout treatment options

AstraZeneca study shows limitations of current gout treatment options

29th October 2013

AstraZeneca and Ardea Biosciences have presented their findings from a new study that sheds light on the limitations of current therapy options for gout patients.

The Lasso trial was a multinational six-month observational study involving 1,735 patients, which was designed to evaluate the safety and efficacy of allopurinol, a commonly used therapy that lowers uric acid levels in gout sufferers.

It was found that fewer than half of the patients taking allopurinol achieved their target serum uric acid level, leaving them at risk of further disease progression and long-term health consequences.

Allopurinol is a generic treatment that has been available for more than 50 years, with this study suggesting that the development of new therapy approaches could be helpful.

Study co-author Dr Nicola Dalbeth of the University of Auckland said: "Gout is a painful form of arthritis that is often misunderstood and inadequately treated. The Lasso study demonstrates that many patients with gout fail to reach the recommended treatment goal."

Ardea Biosciences was purchased last year by AstraZeneca and is currently developing a new therapy for gout called lesinurad, which is undergoing phase III testing.ADNFCR-8000103-ID-801654492-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.